## Johnson Matthey Inspiring science, enhancing life

Presentation of preliminary results for the year ended 31<sup>st</sup> March 2017

0000000

1st June 2017

### Cautionary statement

This presentation contains forward looking statements that are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which Johnson Matthey operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results to differ materially from those currently anticipated.

### Progress on further strengthening our business




### Strong H2 led to full year performance in line with expectations

Year ended 31 <sup>st</sup>	March 2017	YoY growth	YoY growth, continuing businesses at constant rates
LTIIR <sup>1</sup>	0.49	+32%	
Sales	£3,578m	+13%	+3%
Underlying operating profit	£513.3m	+14%	-
Underlying EPS	209.1p	+17%	
Working capital days	54 days	-2 days	
Сарех	£265m	+3%	
R&D	£201m	+7%	
Dividend per share	75.0p	+5%	



JM

### Driving improving performance







Chief Financial Officer

JM

# Full year underlying results in line with expectations following stronger H2

Year ended 31st March <sup>1</sup>	2017 £m	2016 £m	% change	% change, constant rates for continuing businesses
Sales excluding precious metals	3,578	3,177	+13	+3
Operating profit	513	451	+14	-
Finance charges	(32)	(33)	+2	
Profit before tax	482	418	+15	+1
Taxation	(82)	(67)	-22	
Profit after tax	400	351	+14	
Earnings per share	209.1p	178.7p	+17	
Ordinary dividend per share	75.0p	71.5p	+5	

JM

1. All figures are before amortisation of acquired intangibles, major impairment and restructuring charges, profit or loss on disposal of businesses, significant tax rate changes and, where relevant, related tax effects


### Improving performance with stronger H2 sales growth

#### Sales growth for year ended 31<sup>st</sup> March 2017, %<sup>1</sup>

	H1	H2	FY
Emission Control Technologies	+3	+5	+4
Process Technologies	-12	+13	-
Precious Metal Products	-2	+14	+6
Fine Chemicals	+4	-2	+1
New Businesses	+13	+8	+10
Johnson Matthey	-1	+6	+3

### Delivering cost savings and efficiency gains to underpin operating profit

**Underlying operating profit** 




JM

### Improving performance with stronger H2 operating profit growth

#### **Operating profit growth for year ended 31<sup>st</sup> March 2017, %**<sup>1</sup>

H1	H2	FY
_	+3	+2
-1	+18	+9
+4	+31	+17
-26	-20	-23
+11	+12	+12
-3	+4	-
-	- -1 +4 -26 +11	- $+3$ $-1$ $+18$ $+4$ $+31$ $-26$ $-20$ $+11$ $+12$

### ECT: technology driven outperformance in the majority of markets



#### Sales up 4%

- LDV catalyst sales ahead of global production
- HDD sales outperformed in every region
- Benefited from sales of higher value catalysts and business wins


#### **Operating profit up 2%**

 Despite higher initial costs for new products

#### 2017/18 outlook

- Sales growth driven by tightening legislation and business wins
- Margin will be broadly maintained

### PT: managing a cyclical market through cost savings



#### Held sales in the year

- Licensing and first fill income affected by cyclical demand
- Business wins in catalysts offset market weakness


#### **Operating profit up 9%**

• Delivering efficiency gains

#### 2017/18 outlook

- Cyclical recovery not expected next year
- Partially offset by efficiency gains

### PMP: actions taken accelerated H2 performance



#### Sales up 6%

- Higher pgm prices and improved intakes
- Steady growth in Manufacturing

#### **Operating profit up 17%**

- Improved intakes, pgm prices and operating efficiency
- H1 benefited from PRMB<sup>2</sup> credit

#### 2017/18 outlook


- Improved trends to continue
- Lapping PRMB<sup>2</sup> credit will impact operating profit growth

Excluding precious metals 1. 2.

Post-retirement medical benefit. £6m credit to Precious Metal Products in 2016/17 All % figures at constant rates for continuing businesses

# Fine Chemicals: building a wider portfolio to deliver consistent growth

#### Sales<sup>1</sup>



#### Sales up 1%

- Strong contribution from APIs for two newly approved drugs
- Lower sales of ADHD APIs


#### **Operating profit down 23%**

 Impacted by lower sales of higher margin ADHD APIs

#### 2017/18 outlook

- Improved performance
- Continue to invest to in building API product portfolio

### New Businesses: accessing additional areas of potential growth



#### Sales up 10%

- Weak LFP battery material market in H2
- Sales growth and improving productivity in Fuel Cells

#### **Operating loss reduced**

- Improved profitability in Battery Technologies
- Fuel Cells benefited from 2015/16 restructuring

#### 2017/18 outlook

- Uncertainty around LFP likely to remain
- Progress in underlying profitability
- Continued progress in the development of nickel based battery materials

### 17% EPS growth driven mainly by foreign exchange

Year ended 31st March <sup>1</sup>	2017 £m	2016 £m	% change	% change, constant rates for continuing businesses
Sales excluding precious metals	3,578	3,177	+13	+3
Operating profit	513	451	+14	flat
Finance charges	(32)	(33)	+2	
Profit before tax	482	418	+15	+1
Taxation	(82)	(67)	-22	
Profit after tax	400	351	+14	
Earnings per share	209.1p	178.7p	+17	
Ordinary dividend per share	75.0p	71.5p	+5	

JM


1. All figures are before amortisation of acquired intangibles, major impairment and restructuring charges, profit or loss on disposal of businesses, significant tax rate changes and, where relevant, related tax effects

### Focus on consistent delivery of strong cash

Year ended 31st March 2017	£m	
Underlying operating profit		513
Depreciation and amortisation <sup>1</sup>		157
Increase in inventories	(37)	
Increase in receivables	(111)	
Increase in payables	121	
Net working capital outflow		(27)
Net interest paid		(37)
Tax paid		(59)
Capex spend		(256)
Other		(61)
Free cash flow		230

#### **Free cash flow**


Working capital days<sup>2</sup>






### Strong balance sheet


	£m	£m
Net debt at the beginning of the year		(675)
Free cash flow	230	
Dividends	(139)	
Acquisitions	(25)	
Other	(13)	
Movement in net debt before FX		53
Net debt before FX		(622)
FX		(94)
Net debt at the end of the year		(716)



### ROIC improved in the year

Year ended 31 March






JM

### Dividend per share up 5%

#### **Ordinary dividend per share** (pence) Year ended 31<sup>st</sup> March



## Increase reflects confidence in group's medium term prospects

- Driving stronger top line
- Delivering efficiency across the business
- Investing for growth
- Continuing to deliver strong cash

### Looking forward

Improving performance

Stronger sales growth in 2017/18 in line with H2 2016/17

Stronger performance in 2017/18

Targeting further cost savings of around £25m in a full year and £10m in 2017/18

Offset by higher non-cash pension charges and no PRMB in 2017/18

### My three focus areas

Rigorous and transparent resource allocation

Disciplined management of working capital to drive continued strong cash

Drive increasing business wide efficiency



### Changing our organisation to drive performance

Building strong leadership team using external hires and benchmarks

Disciplined process management supported by increased investment

Retain strong local accountability

Standardisation of data and performance metrics to drive synergy

Drive functional excellence

### Better aligned for stronger performance



plus New Markets across all these areas

### Sustainable leading science and technology platforms



Provision of customised solutions Development of new and next-generation products Scale-up of complex manufacturing

...applied to solve customers' problems







### Clean Air: building a flexible global emissions control business



The focus on air quality in Europe will drive growth in medium term, notwithstanding a decline in diesel share



Significant growth opportunities in Asia




JM

Building a flexible and efficient business

### Clean Air in Europe & NA: medium term growth, long term value

Sales % 2016/17



- North America LDV
- North America HDD
- Asia LDV
- Asia HDD
- Other

Supported by:

#### • In the short to medium term:


- New business wins already secured
- Tighter legislation (Euro 6c and real world driving standards)
- Increased focus on tighter emissions from OEMs
- Recovery of Class 8 US truck market

#### • In the long term:

- The importance of air quality as a focus area
- Managing our flexible cost base and manufacturing footprint

### Clean Air: significant growth opportunities in Asia

Sales % 2016/17



Asia LDV
Asia HDD
Europe LDV

- Europe HDD
- North America LDV
- North America HDD

Other

- Well-positioned in China and India
- Winning business with local manufacturers
- Significant vehicle growth expected
- Move to Euro 6 equivalents in China and India for both light and heavy duty
  - Significant value uplift per vehicle
  - Expected to more than double size of our China and India businesses

### Efficient Natural Resources: investing for growth through the cycle





Positioned for recovery in chemicals

#### Improved management of our PGM refineries



JN

Cost efficiency improved

### Efficient Natural Resources: positioned for chemicals market recovery

12 25 12 45 6 Licences and first fills

Licences and first fills
Refill catalysts and additives
Diagnostic services
PGM services
PGM manufacturing

Sales % 2016/17

- Demand for licences and first fills linked to
  - Level of plant builds
  - Capacity in many markets
- High levels of demand not expected to return for a few years
- Well-positioned for future recovery
- Refill catalyst cycle lengthened but market remains stable
- Focused on efficient running of our operations

### Health: investing in an attractive market with long term growth





#### Strong set of core capabilities

#### Investing to expand our business and API product portfolio




#### Improving operational efficiency

N

### Health: investing to expand our business and API product portfolio

#### Sales % 2016/17



Opiate-based APIs

- ADHD APIs
- Other APIs
- Contract development and manufacturing

- \$650bn global pharmaceutical market growing mid to high single digits
- Expanding our capacity in Europe
- Building our future API product portfolio:
  - Over 40 new projects in our pipeline
  - Sales will build over the next three years as plan to launch over 10 new projects and submit over 20 filings
  - Larger portfolio will smooth variability in our sales and profit trends

### New Markets: accessing additional areas of potential growth in...



#### Clean Air: Alternative powertrains

- Developing high energy battery materials, incl. high nickel
- Improved performance in Fuel Cells business



#### Agrochemicals and Medical Device Components



#### Maintaining strict capital discipline

### **Rigorous approach to capital allocation**

**Focused R&D<sup>1</sup>** 

**High levels of capex** £m £m, excluding development costs 250.0 300.0 6 18 250.0 200.0 16 15 5 44 29 44 200.0 22 17 10 150.0 44 77 57 43 150.0 43 81 100.0 100.0 80 75 87 68 71 50.0 68 50.0 49 33 33 40 29 19 0.0 0.0 2014/15 2015/16 2016/17 2014/15 2015/16 2016/17 Efficient Natural Resources Health New Markets Clean Air Central Capex 1.7x depreciation 2016/17: R&D 5.6% of sales JM 1. R&D includes capitalised development costs (£18.9 million in 2016/17) 35

### Conclusion

#### Strategy aligned to global growth drivers


#### Stronger sales growth in 2017/18

#### Cost efficiency and improved functional excellence

#### Margin expansion beyond next year




### 17% EPS growth driven mainly by foreign exchange



### Global growth in vehicle production

Light duty vehicle production outlook (million) Calendar years



**CAGR 2.4%** 

JM


### Light duty emissions control legislation roadmap

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	202
Europe	EU	6b		EU 6c / RI	DE Phase 1			DE Phase 2 95 g/km CC		EU	7?
North America EPA	Tie	r 2			Tier 3 Pl	nase In: I	NMOG + NO	Dx, PM Tigh	itening		
North America CARB	LE	V III Phas	II Phase In: NMOG + NOx, PM Tightening LEV III Further Tighte							ghtening	
Japan		JP09					JP18				
South Korea (Gasoline)	K-ULEV			K-ULEV 70				LEV I	[] / 97g/k	m CO <sub>2</sub>	
South Korea (Diesel)		EU	6b		EU 6c/ RD 1	E Phase		DE Phase 2 97g/km CO	-	EU	7?
China (Beijing)	BJ5 (	EU 5)		BJ6			China	6b		China 6b /	DDE
China (Nationwide)	Cł	nina 4 (EU	4)	China	a 5 (EU 5)		China	ба			RUE
India			BS4 (EU	4)			BS6 (E	U 6)		BS6 / RI	DE
Indonesia		EL	J 2					EU 4			
Thailand		EU	J 4				EU5			EU6	

2025

### Heavy duty diesel vehicle production (regulated engines)

Heavy duty diesel vehicle (regulated engines) production outlook (thousands) Calendar years



**CAGR 5.7%** 

### Heavy duty diesel emissions control legislation roadmap

#### On Road

#### Europe North America

North America (CARB)

Japan

South Korea

Brazil

Russia

India (Main Cities)

India (Nationwide)

China (Beijing)

China (Nationwide)

#### Non-road

Europe North America Japan South Korea Brazil China (Beijing) China (Nationwide)

2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
				EU VI EU					VII?	
		GHG PI	nase 1				GHO	FPhase 2		
	GHG Phase 1						GHG Phase 2 CARB Ultra Low N			
JP09						JP16				
EU VI									EU VI?	
			EU IV			EU V?				
El	U IV			EL	J V?			E	U VI?	
		BS IV			BS	VI		BS V	'I / PEMS	
BS III			BS IV		BS		BS VI / PEMS			
China V					China VI					
Chi	ina IV		China V		China	VIa		Ch	ina VIb	

Tier 4b		Stage V				
Tier 4b				CARB/EP/	A Reduced NOx/PM?	
		Tier 4b				
Tier	Tier 4b			Stage V?		
Tier 3	Tier 3			4a?	Tier 4b?	
Tier 3	Tier	r 4a		Tier 4b?		
Tier 3			Tier 4a Tier 4b			Tier 4b?

## Johnson Matthey Inspiring science, enhancing life

7

DECENTRATION OF